Renaissance Technologies
LVTX

Renaissance Technologies’s LAVA Therapeutics LVTX Stock Holding History

Renaissance Technologies’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,600
Closed -$18K – 4118
2023
Q1 		$18K Sell
10,600
-8,200
-44% -$23K ﹤0.01% 3839
2022
Q4 		$66K Buy
+18,800
New +$86.3K ﹤0.01% 3737

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Renaissance Technologies's LVTX Position: Q2 2023 in Review

Renaissance Technologies sold out of LAVA Therapeutics (LVTX) in Q2 2023, closing a stake of 10,600 shares — an estimated $18K sold.

Renaissance Technologies first reported a position in LVTX in Q4 2022 and held it in 2 quarters. The position peaked at $66K in Q4 2022. 15 funds tracked by Wall St. Rank hold LVTX as of Q2 2023.

  • Renaissance Technologies reported no remaining LAVA Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Renaissance Technologies sold 10,600 LAVA Therapeutics shares in Q2 2023, an estimated $18K.
  • Renaissance Technologies first reported a position in LAVA Therapeutics in Q4 2022 and held it in 2 quarters.
  • Renaissance Technologies's LAVA Therapeutics position peaked at $66K in Q4 2022.
  • 15 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.